Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03448835 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

Study acronym: PANDA
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 10 words Publications: details revised at 2 of 2 entries Show 1 more changeShow less
    • Publications: details revised at 2 of 2 entries
  2. Primary and study completion dates: Jan 1, 2022 to Oct 31, 2026 Trial status: Recruiting to Active, Not Recruiting · Site details revised at 2 of 2 sitesv6 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
  3. Study sites revised (2)v5 See this version in full on ClinicalTrials.gov ↗
  4. Primary completion date: Jan 1, 2020 to Jan 1, 2022 Study sites: 1 to 2 · Completion date: Jan 1, 2021 to Jan 1, 2022v4 Show 2 more changesShow less
    • Study sites: 1 to 2
    • Completion date: Jan 1, 2021 to Jan 1, 2022
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting Start date: Apr 1, 2018 to Mar 7, 2018 · Site details revisedv2 Show 2 more changesShow less
    • Start date: Apr 1, 2018 to Mar 7, 2018
    • Site details revised
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment. The treatment will be 1 cyle atzolizumab monotherapy, followed by 4 cycle of atezolizumab and capecitabine, oxaliplatin and docetaxel.
Trial Details
NCT Number NCT03448835
Lead Sponsor The Netherlands Cancer Institute
Collaborators: Hoffmann-La Roche
Conditions Stomach Cancer, Gastro Esophageal Junction Cancer
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov